Meeder Asset Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-20
Closed 1579
2022
Q3
$0 Sell
20
-65
-76% -$2.82K ﹤0.01% 2294
2022
Q2
$4K Buy
85
+5
+6% +$259 ﹤0.01% 1718
2022
Q1
$6K Buy
+80
New +$7.13K ﹤0.01% 1735
2021
Q4
Sell
-2,164
Closed -$448K 1951
2021
Q3
$448K Sell
2,164
-119
-5% -$26.2K 0.02% 467
2021
Q2
$485K Buy
2,283
+449
+24% +$82.3K 0.02% 517
2021
Q1
$334K Buy
+1,834
New +$365K 0.02% 607
2020
Q4
Sell
-2,059
Closed -$224K 2112
2020
Q3
$224K Buy
2,059
+676
+49% +$82.4K 0.01% 580
2020
Q2
$116K Buy
1,383
+972
+236% +$37.2K 0.01% 735
2020
Q1
$6K Sell
411
-178
-30% -$1.51K ﹤0.01% 1721
2019
Q4
$2K Buy
589
+102
+21% +$442 ﹤0.01% 2037
2019
Q3
$2K Buy
487
+235
+93% +$1.29K ﹤0.01% 1973
2019
Q2
$1K Buy
+252
New +$1.98K ﹤0.01% 1963
2019
Q1
Sell
-104
Closed -$4K 1802
2018
Q4
$4K Buy
+104
New +$4.03K ﹤0.01% 1468
2018
Q2
Sell
-53
Closed -$2K 1642
2018
Q1
$2K Buy
53
+13
+33% +$522 ﹤0.01% 1384
2017
Q4
$1K Sell
40
-124
-76% -$3.02K ﹤0.01% 1578
2017
Q3
$4K Sell
164
-60
-27% -$1.34K ﹤0.01% 1327
2017
Q2
$5K Hold
224
﹤0.01% 1197
2017
Q1
$6K Sell
224
-34
-13% -$935 ﹤0.01% 1012
2016
Q4
$6K Buy
+258
New +$7.53K ﹤0.01% 836

Other funds holding NVAX

Meeder Asset Management's NVAX Position: Q4 2022 in Review

Meeder Asset Management sold out of Novavax (NVAX) in Q4 2022, closing a stake of 20 shares.

Meeder Asset Management first reported a position in NVAX in Q4 2016 and held it in 19 quarters. The position peaked at $485K in Q2 2021. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

  • Meeder Asset Management reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 20 Novavax shares in Q4 2022.
  • Meeder Asset Management first reported a position in Novavax in Q4 2016 and held it in 19 quarters.
  • Meeder Asset Management's Novavax position peaked at $485K in Q2 2021.
  • 252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.